Latest News & Blog

Inspiring & original thinking. And, the latest news about us.

THINKING

Welcome to Well Filtered™

A blog series dedicated to unearthing the ideas, perspectives, and innovations that matter most in kidney health.

Is there real value in value-based care? 02.08.22

A SPECIAL, NEW YEAR INVESTIGATIVE BLOG: Making Sense of Population Health, Precision Medicine & Value-Based Care with Mount Sinai’s Dr. Arshad Rahim 01.06.22

An “Inside Look” at Precision Medicine, Cardiovascular & Kidney Disease: We Get It Straight from Bayer’s, Dr. Amit Sharma 10.26.21

A “How To” Playbook for Disrupting Kidney Care: Our Live Chat with the National Kidney Foundation’s Chief Medical Officer 09.20.21

Are Kidney-Focused Clinical Studies Finally Hitting Their Groove? The Trials to Watch & Why 08.10.21

3 Ways We’re Translating Lessons Learned in Cancer to Help Fix the Kidney Care Model 7.27.21

6 Tipping Point Innovations in Kidney Care: A Leading Expert Shares His POV 6.28.21

Why a Shift in Thinking from Kidney Disease to Kidney Health is Mission-Critical. A Candid Conversation with NKF’S Former President & Board Member, Holly Kramer. 6.02.21

NEWS

Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions 04.08.21
Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) announces findings presented in a Late-Breaking presentation at

Read More
Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure 04.05.21
Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted

Read More
Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics 03.15.21
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provides an update

Read More
Renalytix AI plc Issue of Shares Under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights 03.04.21
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that

Read More
RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 03.02.21
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance

Read More
The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health 02.24.21
Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease NEW YORK and SALT LAKE CITY, Feb.

Read More
RenalytixAI to announce Financial Results for six and three months ended December 31, 2020 02.23.21
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance

Read More
American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health 02.04.21
Event Featuring Leading Clinicians, Biotech Innovators and Federal Health Agencies to Highlight Innovation and Opportunity in Kidney Health NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company,

Read More
Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics 01.13.21
Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway ( RIN:

Read More
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita 01.05.21
First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costs NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX)

Read More